wang wei

Author    Correspondence author
Cancer Genetics and Epigenetics, 2024, Vol. 12, No.   
Received: 01 Jan., 1970    Accepted: 01 Jan., 1970    Published: 11 Oct., 2024

Abstract The von Hippel-Lindau (VHL) gene plays a crucial role in the pathogenesis of clear cell renal cell carcinoma (ccRCC), both in hereditary and sporadic forms. This study explores the application and future prospects of VHL gene research in the diagnosis and treatment of kidney cancer. VHL inactivation, through mutations, loss of heterozygosity, or promoter hypermethylation, is a common event in ccRCC, leading to the stabilization of hypoxia-inducible factors (HIFs) and subsequent activation of angiogenic pathways. Recent studies have highlighted the significance of VHL gene alterations in predicting disease prognosis and therapeutic responses. Integrated genomic analyses have identified VHL as a key player in the molecular landscape of ccRCC, providing insights into potential therapeutic targets. Furthermore, the development of anti-angiogenic therapies targeting the VHL-HIF-VEGF/VEGFR pathway has revolutionized the treatment of metastatic ccRCC. This study also discusses the emerging role of VHL gene status in guiding personalized treatment strategies and the potential of novel biomarkers for early diagnosis and prognosis. The ongoing research on VHL gene alterations holds promise for improving the clinical management of kidney cancer.